国产替罗非班治疗急性冠脉综合征的临床观察

Clinical observation for using Tirofiban in acute coronary syndrome patients

目的评价替罗非班在急性冠脉综合征介入治疗中的临床疗效和安全性。方法436例急性冠脉综合征患者在进行冠脉介入治疗前根据是否应用替罗非班分为标准治疗组(220例)和替罗非班组(216例),对比两组介入术中罪犯血管TIMI血流和发生无复流现象情况,观察应用硝酸甘油和替罗非班冠脉注射改善无复流现象的效果,观察两组不良心血管事件和出血情况。结果替罗非班组术前、术后罪犯血管TIMI血流明显高于标准治疗组(P<0.05),术中无复流现象发生明显低于标准治疗组(P<0.05)。介入术中发生无复流现象后,冠状动脉内注射替罗非班比硝酸甘油更为有效地改善无复流现象(P<0.05),而不增加出血并发症。结论术前应用替罗非班可以有效改善罪犯血管TIMI血流并预防无复流现象发生,冠状动脉内注射替罗非班可以有效改善无复流现象,安全性高。

Objective To investigate the clinical effect and safety of Tirofiban on acute coronary syndrome （ACS）patients with PCI therapy. Methods 436 ACS patients were divided into Tirofiban group（n=216）and normal group（n=220）aceording to whether using tirofiban,compared with each other for TIMI flow and no-reflow phenoment of crisis vascular before and after PCI operation,when no-reflow phenoment occured, evaluated result of using Tirofilban and nitroglycerine for Therapy no-reflow phenoment ,observed major adveree cardic effect and bleeding ease. Results Used Tirofiban before PCI operation can improve TIMI flow and had less no-reflow occur than normal group （P〈0.05）, using Tirofiban can reduce no-reflow phenoment and had good effect to no-reflow therapy than nitroglycerine （P〈0.05） without increase bleeding ease. Conclusion Using Tirofiban before PCI can improved TIMI flow in crisis vascular effectly and prevent no-reflow occur,reduce chest pain and heart failure after three month for PCI,using Tirofiban by coronary inject is a good method for therapy no-reflow phenoment. It is safety.